ArticleEmerging infectious diseases2017
Serogroup B Meningococcal Disease Vaccine Recommendations at a University, New Jersey, USA, 2016.
Article in Emerging infectious diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Outbreaks of meningococcal meningitis in non-African countries over the last 50 years: a systematic review.Journal of global health · 2019Pooled it
- Presentations at the UK National Immunisation Conference.Human vaccines & immunotherapeutics · 2022Article
- Herd Protection against Meningococcal Disease through Vaccination.Microorganisms · 2020Review
- [Health Technology Assessment of meningococcal B vaccine (TrumenbaJournal of preventive medicine and hygiene · 2019Article
- University-Based Outbreaks of Meningococcal Disease Caused by Serogroup B, United States, 2013-2018.Emerging infectious diseases · 2019Article
- Cost Effectiveness of Meningococcal Serogroup B Vaccination in College-Aged Young Adults.American journal of preventive medicine · 2019Article
- Cost calculator for mass vaccination response to a US college campus outbreak of serogroup B meningococcal disease.Human vaccines & immunotherapeutics · 2019Article
- Optimal use of meningococcal serogroup B vaccines: moving beyond outbreak control.Therapeutic advances in vaccines and immunotherapy · 2018Review
- Serum Bactericidal Antibody Responses of Students Immunized With a Meningococcal Serogroup B Vaccine in Response to an Outbreak on a University Campus.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2017Article
- Breadth and Duration of Meningococcal Serum Bactericidal Activity in Health Care Workers and Microbiologists Immunized with the MenB-FHbp Vaccine.Clinical and vaccine immunology : CVI · 2017Article
- The role of anti-NHba antibody in bactericidal activity elicited by the meningococcal serogroup B vaccine, MenB-4C.Vaccine · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In response to a university-based serogroup B meningococcal disease outbreak, the serogroup B meningococcal vaccine Trumenba was recommended for students, a rare instance in which a specific vaccine brand was recommended. This outbreak highlights the challenges of using molecular and immunologic data to inform real-time response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.